RayOne Family
RayOne® fully preloaded IOL injection system, designed to deliver without compromise.
At Rayner, we believe that the only way to create a true, fully preloaded micro incision cataract surgery (MICS) injection system that works consistently without compromise, is to design the system as one - both lens and injector. This was the inspiration behind RayOne®
Preloaded Primary IOL Platform
X
Vacuole free material for a glistening free IOL
- Single piece IOL created from Rayacryl® a homogeneous material free of microvacuoles, resulting in a glistening free IOL8
- Compressible material for delivery through a small incision
- Excellent handling characteristics with controlled unfolding within the capsular bag
- Low silicone oil adherence9
- Excellent uveal biocompatibility13
- Hydrophilic acrylic material with low inflammatory response10
X
Reliable optical outcomes and a low rate of post-operative complications
Designed with Rayner's Anti-Vaulting Haptic (AVH) Technology® .Our RayOne® IOL provides proven rotational and centrational stability, and excellent fixation in the capsular bag1
- Superb centration
– Maximum offset of only 1 mm 3 months after surgery2 - Excellent rotational and torsional stability
– 3.1° mean IOL rotation 3 months after surgery2
X
360° Optimised Barrier to reduce PCO – Low Nd: YAG capsulotomy rates
Rayner's 360° Amon-Apple Enhanced Square Edge creates an optimum barrier to reduce epithelial cell migration including at the haptic-optic junction7,5
| MEAN TIME TO ND:YAG CAPSULOTOMY7 | |
| At 12 months | 0.6% |
| At 24 months | 1.7% |
| ND:YAG CAPSULOTOMY RATES7 |
|
9.3 ± 5.5 months Follow-up period: 5.3 – 29 months |
Study of 3,461 patients receiving Rayner 570C IOLs over a 24 month period, Nd:YAG capsulotomy rates were extremely low and comparable with hydrophobic acrylic lenses with square-edge optics.7
X
Reducing dysphotopsia by design12
- Rayner’s Enhanced Square Edge Technology shows no general increase in glare from previous models without a square edge7
- The low refractive index (1.46) of Rayacryl®
References:
- Claoué C. Clinical and Surgical Ophthalmology 2008; 26(6): 198-200
- Alberdi R et al. J Refract Surg. 2012; 28(10):696-700
- Nanavaty MA et al. J Cataract Refract Surg. 2009; 35:663–671
- Yagci R et al. Eur J Ophthalmol. 2014 Jul 24; 24(5):688-92
- Vyas AV et al. J Cataract Refract Surg 2007; 33:81-87
- Johansson B et al. J Cataract Refract Surg. 2007; 33:1565–1572
- Mathew RG and Coombes AGA. Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec; 41(6):651-5
- Rayner. Data on File. White paper
- McLoone E et al. Br J Ophthalmol. 2001; 85:543–545
- Richter-Mueksch S et al. J Cataract Refract Surg. 2007; 33:1414–1418
- Altmann GE et al. J Cataract Refract Surg. 2005; 31(3): 574-585
- Cezón Prieto J and Bautista MJ. J Cataract Refract Surg. 2010; 36:1508-1516
- Tomlins PJ et al. J Cataract Refract Surg. 2014; 40:618–625
- Pepose JS et al. Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):965-73
*Of those who expressed a preference
RAYTRACE
OVDs
